RebrAIn
RebrAIn offers accurate targeting technology for Deep Brain Stimulation thanks to an algorithm based on Artificial Intelligence.
- dt and ls
- core ai
- radar de l'innovation
- ai applications
- observatoire industrial tech
- observatoire deeptech
- neurology
- surgery
- biotech, medtech and e-health
- tech for medical professionals
- physician support tools
- observatoire healthtech
- medical imaging
- clinical decision support
- virtual assistant
- degenerative diseases
- neuromodulation and neurostimulation
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
* | €3.7m | Seed | |
| Total Funding | 000k | ||
Related Content
Rebrain is a pioneering company specializing in treatments for neurodegenerative diseases. Utilizing advanced algorithms, Rebrain offers precise targeting technology for Deep Brain Stimulation (DBS), a medical procedure that involves implanting electrodes in the brain to treat disorders such as Parkinson's disease and epilepsy. The company's core product, OptimDBS software, simplifies and reduces the trauma associated with DBS surgeries by providing doctors with highly accurate targeting information, thereby improving patient outcomes and reducing operative time.
Rebrain primarily serves medical professionals and healthcare institutions that specialize in neurology and neurosurgery. Operating in the healthcare technology market, the company employs a B2B (business-to-business) model, selling its software solutions directly to hospitals and clinics. Revenue is generated through the sale of software licenses and ongoing support services.
Keywords: neurodegenerative, Deep Brain Stimulation, algorithms, OptimDBS, neurology, neurosurgery, healthcare technology, B2B, software licenses, medical professionals.